Aerovate Therapeutics Stock Performance
| AVTE Stock | USD 2.68 0.02 0.75% |
On a scale of 0 to 100, Aerovate Therapeutics holds a performance score of 13. The firm shows a Beta (market volatility) of 1.01, which signifies a somewhat significant risk relative to the market. Aerovate Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Aerovate Therapeutics is expected to follow. Please check Aerovate Therapeutics' downside variance, and the relationship between the treynor ratio and kurtosis , to make a quick decision on whether Aerovate Therapeutics' price patterns will revert.
Risk-Adjusted Performance
13 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Aerovate Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating basic indicators, Aerovate Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 1.88 | Five Day Return 1.5 | Year To Date Return (87.57) | Ten Year Return (88.13) | All Time Return (88.13) |
1 | Disposition of 2016 shares by George Eldridge of Aerovate Therapeutics at 2.14 subject to Rule 16b-3 | 09/05/2024 |
2 | Disposition of 6387 shares by Gillies Hunter of Aerovate Therapeutics at 25.8137 subject to Rule 16b-3 | 09/18/2024 |
3 | Heres Why Aerovate Therapeutics Must Use Its Cash Wisely - Simply Wall St | 10/01/2024 |
4 | Disposition of 503 shares by Gillies Hunter of Aerovate Therapeutics at 1.74 subject to Rule 16b-3 | 10/24/2024 |
5 | Shareholder Alert Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders | 10/31/2024 |
| Begin Period Cash Flow | 22.4 M | |
| Free Cash Flow | -56.9 M |
Aerovate |
Aerovate Therapeutics Relative Risk vs. Return Landscape
If you would invest 186.00 in Aerovate Therapeutics on August 28, 2024 and sell it today you would earn a total of 82.00 from holding Aerovate Therapeutics or generate 44.09% return on investment over 90 days. Aerovate Therapeutics is currently generating 0.6444% in daily expected returns and assumes 3.6458% risk (volatility on return distribution) over the 90 days horizon. In different words, 32% of stocks are less volatile than Aerovate, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Aerovate Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aerovate Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Aerovate Therapeutics, and traders can use it to determine the average amount a Aerovate Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1767
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | AVTE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.65 actual daily | 32 68% of assets are more volatile |
Expected Return
| 0.64 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 13 87% of assets perform better |
Based on monthly moving average Aerovate Therapeutics is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Aerovate Therapeutics by adding it to a well-diversified portfolio.
Aerovate Therapeutics Fundamentals Growth
Aerovate Stock prices reflect investors' perceptions of the future prospects and financial health of Aerovate Therapeutics, and Aerovate Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Aerovate Stock performance.
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.49 | ||||
| Current Valuation | (11.38 M) | ||||
| Shares Outstanding | 28.87 M | ||||
| Price To Earning | 0.64 X | ||||
| Price To Book | 0.95 X | ||||
| EBITDA | (81.31 M) | ||||
| Net Income | (75.52 M) | ||||
| Cash And Equivalents | 151.99 M | ||||
| Cash Per Share | 6.22 X | ||||
| Total Debt | 675 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 40.85 X | ||||
| Book Value Per Share | 2.79 X | ||||
| Cash Flow From Operations | (56.78 M) | ||||
| Earnings Per Share | (2.99) X | ||||
| Market Capitalization | 76.81 M | ||||
| Total Asset | 127.42 M | ||||
| Retained Earnings | (163.42 M) | ||||
| Working Capital | 106.59 M | ||||
About Aerovate Therapeutics Performance
By analyzing Aerovate Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Aerovate Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Aerovate Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Aerovate Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.59) | (0.62) | |
| Return On Capital Employed | (0.74) | (0.78) | |
| Return On Assets | (0.59) | (0.62) | |
| Return On Equity | (0.69) | (0.66) |
Things to note about Aerovate Therapeutics performance evaluation
Checking the ongoing alerts about Aerovate Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Aerovate Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Aerovate Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (75.52 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Aerovate Therapeutics currently holds about 151.99 M in cash with (56.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Aerovate Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from businesswire.com: Shareholder Alert Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders |
- Analyzing Aerovate Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Aerovate Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Aerovate Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Aerovate Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Aerovate Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Aerovate Therapeutics' stock. These opinions can provide insight into Aerovate Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Aerovate Stock analysis
When running Aerovate Therapeutics' price analysis, check to measure Aerovate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aerovate Therapeutics is operating at the current time. Most of Aerovate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aerovate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aerovate Therapeutics' price. Additionally, you may evaluate how the addition of Aerovate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |